Streetbeat News

Products Services

IBM

NVDA

SSNLF

IBM is considering using its in-house AI chips to reduce the costs of its new cloud service, Watsonx. The chips, manufactured by Samsung, are power efficient and could lower cloud service costs. IBM is not aiming to replace Nvidia's semiconductors, but to make AI systems more cost-efficient. IBM also plans to replace nearly 8,000 jobs with AI in the coming years.

Portfolio Pulse from Anusuya Lahiri

July 12, 2023 | 12:54 pm

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc, has deprioritized its AI-powered mobile chatbot app, 'Bubble Characters', due to an internal reorganization. The app, aimed at Gen Z users, utilized large language models and massive data sets to generate human-like text. The company has shifted focus to another chatbot project called Bard. Several top AI researchers from Google have left to establish their own chatbot companies, such as Character.AI.

Portfolio Pulse from Anusuya Lahiri

July 12, 2023 | 12:52 pm

TLRY

Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) has launched new ready-to-drink, sparkling THC beverages under its RIFF brand. The beverages, available in two flavors, are sold in Alberta and Ontario, with national distribution expected later this year. The company claims that the beverages offer a quick onset of effects due to fast-acting nano-emulsified THC.

Portfolio Pulse from Vuk Zdinjak

July 12, 2023 | 12:42 pm

ONDS

Ondas Holdings Inc. (NASDAQ:ONDS) has announced that the US Federal Aviation Administration (FAA) has approved the noise certification standards for its Optimus-1EX system, a significant step towards completing the Type Certification process. This will allow the Optimus System to operate more broadly in urban environments in the US. The Airobotics drone-in-a-box solution, already deployed in the UAE and Israel, relies on automated drones that do not require human intervention. The company expects to secure the formal Type Certificate during 2023.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 12:39 pm

XXII

22nd Century Group has announced that its VLN products are now available for purchase by hub customers in the Midwest. This expansion could potentially increase the company's market share and revenues.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 12:37 pm

SHPW

Shapeways has announced significant investments in its software offering, including the launch of a 3D model viewer and a refreshed manufacturing brand. The company aims to enhance its digital manufacturing capabilities and provide a more immersive experience for its customers.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 12:37 pm

SNY

TAK

Takeda Pharmaceutical Co Ltd has withdrawn its FDA application for its dengue vaccine, TAK-003, due to data collection issues. The future of TAK-003 in the U.S. will be reevaluated. The vaccine is already approved in several countries. Sanofi SA's Dengvaxia, the first dengue vaccine, saw reduced usage due to increased risk of severe disease in certain children. TAK-003 was granted priority review by the FDA in November last year.

Portfolio Pulse from Vandana Singh

July 12, 2023 | 12:32 pm

SEAT

Vivid Seats has launched the first generative AI live events discovery plugin for ChatGPT. This new tool will allow users to discover live events based on their preferences and interests.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 12:31 pm

CURLF

Curaleaf Holdings, Inc. has launched its first standalone mobile app, available in all 19 states where the company operates. The app allows customers to order cannabis products, receive updates on new products and discounts, and manage reward points via the Curaleaf Rewards Program. The company also revamped its Curaleaf Rewards Program in April 2023, now available at all Curaleaf retail locations.

Portfolio Pulse from Vuk Zdinjak

July 12, 2023 | 12:31 pm

INCY

Incyte Corporation has announced positive topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with atopic dermatitis (AD). The study met its primary endpoint, showing significantly more patients treated with ruxolitinib cream achieved Investigator's Global Assessment Treatment Success than those treated with a non-medicated cream. The safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed. The long-term safety portion of the study will continue as planned.

Portfolio Pulse from Vandana Singh

July 12, 2023 | 12:23 pm